Naveruclif (Paclitaxel)

Paclitaxel binds to β‑tubulin, stabilising microtubules and preventing their depolymerisation during mitosis. This blocks the cell cycle at the G2/M phase, leading to apoptosis of rapidly dividing cancer cells. The mechanism is independent of hormone receptors and targets the structural framework essential for cell division.

The dosage of Naveruclif is determined by the prescribing oncologist based on the specific cancer type, disease stage, patient weight, and organ function. Dosing regimens vary widely, and the prescriber will calculate the appropriate amount and schedule for each individual patient.

The safety of Naveruclif (paclitaxel) in pregnancy and lactation has not been established. It is generally contraindicated in pregnant women because it may harm the fetus, and breastfeeding is not recommended while receiving treatment, as the drug can be excreted in milk.

To order Naveruclif, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including cold‑chain handling if needed) and any required import documentation.

Naveruclif (paclitaxel) belongs to the taxane class, similar to docetaxel. Both agents stabilise microtubules, but paclitaxel is administered intravenously and has a distinct toxicity profile, with higher rates of neuropathy and hypersensitivity reactions. Choice between agents depends on cancer type, prior therapy, and individual patient tolerance.

Naveruclif should be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. Before use, allow the product to reach room temperature if required by the administration protocol.

Naveruclif is given as an intravenous infusion by a qualified healthcare professional. The infusion rate and duration are set by the treating physician, often over 30 minutes to several hours, depending on the prescribed dose and patient tolerance. Premedication may be used to reduce infusion‑related reactions.

The most serious risks include severe neutropenia leading to infection, hypersensitivity reactions that can be life‑threatening, peripheral neuropathy that may become irreversible, and cardiac arrhythmias. Patients should be monitored closely for fever, breathing difficulties, numbness, or any signs of cardiac irregularities during and after infusion.

Naveruclif is contraindicated in patients with known hypersensitivity to paclitaxel or any of its excipients, those with severe uncontrolled infections, and individuals with significant hepatic impairment where dose adjustment is not feasible. Caution is also advised for patients with pre‑existing neuropathy or cardiac conditions.